Abstract
The mechanism of action of both typical antipsychotics and the atypical antipsychotic, clozapine, may be related to the (changing) interaction of dopamine and serotonin in schizophrenia. This study examined the effect of olanzapine in schizophrenic patients on cerebrospinal fluid (CSF) metabolites of dopamine (homovanillic acid, HVA) and serotonin (5-hydroxyindoleacetic acid, 5-HIAA). Twenty-three male schizophrenic patients, who were drug-free for at least 2 weeks (mean drug-free period of 35 days ± 43; median 16 days), underwent a lumbar puncture (LP). Patients were subsequently treated with olanzapine 10 mg/day for 6 weeks, after which the LP was repeated. CSF was assayed for HVA and 5-HIAA concentrations. Psychiatric symptoms were rated once a week. Olanzapine significantly increased HVA concentrations and the HVA/5-HIAA ratio while 5-HIAA concentrations were not altered. These changes did not significantly correlate with treatment response. A negative correlation was found between HVA concentrations and negative symptoms after olanzapine treatment. In conclusion, olanzapine treatment increases HVA concentrations and the HVA/5-HIAA ratio in CSF of schizophrenic patients, but these changes are unrelated to its clinical efficacy.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Agnati LF, Zoli M, Stromberg I, Fuxe K . (1995): Intercellular communication in the brain: wiring versus volume transmission. Neuroscience 69: 711–726
Agren H, Mefford IN, Rudorfer MV, Linnoila M, Potter WZ . (1986): Interacting neurotransmitter systems: a non-experimental approach to the 5HIAA-HVA correlation in human CSF. J Psychiatry Res 20: 175–193
Amin F, Davidson M, Davis KL . (1992): Homovanillic acid measurement in clinical research : a review of methodology. Schizophr Bull 18: 123–141
Andersen O, Johansson B, Svennerholm L . (1981): Monoamine metabolites in successive samples of spinal fluid. Acta Neurol Scand 63: 247–254
Andreasen NC, Flaum M, Arndt S . (1992): The comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 49: 615–623
Asberg M . (1994): Monoamine neurotransmitters in human aggressiveness and violence: A selective review. Crim Behav Ment Health 4: 303–327
Banki CM . (1978): Alterations of cerebrospinal fluid 5-hydroxyindoleacetic acid, and total blood serotonin content during clozapine treatment. Psychopharmacology 56: 195–198
Banki CM, Molnar G . (1981): Cerebrospinal fluid 5-hydroxyindoleacetic acid as an index of serotonergic processes. Psychiatry Res 5: 23–32
Bertilsson L, Asberg M, Lantto O, Scalia-Tomba GP, Traskman-Bendz L, Tybring G . (1982): Gradients of monoamine metabolites and cortisol in cerebrospinal fluid of psychiatric patients and healthy controls. Psychiatry Res 6: 77–83
Bymaster F, Perry KW, Nelson DL, Wong DT, Rasmussen K, Moore NA, Calligaro DO . (1999): Olanzapine: a basic science update. Br J Psychiatry 174(suppl 37):36–40
Carlsson A . (1978): Antipsychotic drugs, neurotransmitters, and schizophrenia. Am J Psychiatry 135: 164–173
Creese J, Burt DR, Snyder SH . (1976): Dopamine receptor binding predicts clinical pharmacological potencies of anti-schizophrenic drugs. Science 192: 481–483
Davis KL, Kahn RS, Ko G, Davidson M . (1991): Dopamine in schizophrenia: a review and reconceptualization. Am J Psychiatry 148: 1474–1486
Doran AR, Boronow J, Weinberger DR, Wolkowitz OM, Breier A, Pickar D . (1987): Structural brain pathology in schizophrenia revisited: prefrontal cortex pathology is inversely correlated with cerebrospinal fluid levels of homovanillic acid. Neuropsychopharmacology 1: 25–32
Duinkerke SJ, Botter PA, Jansen AA, van Dongen PA, van Haaften AJ, Boom AJ, van Laarhoven JH, Busard HL . (1993): Ritanserin a selective 5-HT2/1c antagonist and negative symptoms in schizophrenia. A placebo controlled double blind trial. Br J Psychiatry 163: 451–455
Eklundh T, Eriksson M, Sloberg S, Nordin C . (1996): Monoamine precursors, transmitters and metabolites in cerebrospinal fluid: a prospective study in healthy male subjects. J Psychiat Res 30: 201–208
Elsworth JD, Leahy DJ, Roth RH, Redmond DE Jr . (1987): Homovanillic acid concentrations in brain, CSF and plasma as indicators of central dopamine function in primates. J Neural Transm 68: 51–62
Farde L, Wiesel FA, Halldin C, Sedvall G . (1988): Central D2-dopamine receptor occupancy in schizophrenic patients treated with antipsychotic drugs. Arch Gen Psychiatry 20: 513–517
Fibiger HC, Miller JJ . (1987): An anatomical and electrophysiological investigation of the serotonergic projection from the dorsal raphe nucleus to the substantia nigra in the rat. Neuroscience 2: 975–987
Garelis E, Sourkes TL . (1973): Sites of origin in the central nervous system of monoamine metabolites measured in human cerebrospinal fluid. J Neurosurg Psychiat 36: 625–629
Geracioti TD, West SA, Baker DG, Hill KK, Ekhator NN, Wortman MD, Keck PE, Norman AB . (1999): Low CSF concentration of a dopamine metabolite in tobacco smokers. Am J Psychiatry 156: 130–132
Härnryd C, Bjerkenstedt L, Gullberg B, Oxenstierna G, Sedvall G, Wiesel FA . (1984): Time course for effects of sulpiride and chlorpromazine on monoamine metabolite and prolactin levels in cerebrospinal fluid from schizophrenic patients. Acta Psychiatr Scand 311: S75–S92
Hetey L, Drescher K . (1986): Influence of antipsychotics on presynaptic receptors modulating the release of dopamine synaptosomes of the nucleus accumbens of rats. Neuropharmacology 25: 1103–1109
Hill KK, West SA, Ekhator NN, Bruce AB, Wortman MD, Baker DG, Geracioti TD . (1999): The effect of lumbar puncture stress on dopamine and serotonin metabolites in human cerebrospinal fluid. Neurosci Lett 276 (1): 25–28
Hsiao JK, Colison J, Bartko JJ, Doran AR, Konicki PE, Potter WZ, Pickar D . (1993a): Monoamine neurotransmitter interactions in drug-free and neuroleptic-treated schizophrenics. Arch Gen Psychiatry 50: 606–614
Hsiao JK, Potter WZ, Agren H, Owen RR, Pickar D . (1993b): Clinical investigation of monoamine neurotransmitter interactions. Psychopharmacology 112: S76–S84
Iyer RN, Bradberry CW . (1996): Serotonin-mediated increase in prefrontal cortex dopamine release: pharmacological characterization. J Pharmacol Exp Ther 277: 40–47
Jacobsen LK, Frazier JA, Malhotra AK, Karoum F, McKenna K, Gordon CT, Hamburger SD, Lenane MC, Pickar D, Potter WZ, Rapoport JL . (1997): Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. Am J Psychiatry 154: 69–74
Jibson M, Faull KF, Csernansky JG . (1990): Intercorrelations among monoamine metabolite concentrations in human lumbar CSF are not due to a shared acid transport system. Biol Psychiatry 28: 595–602
Kahn RS, Davidson M, Knott P, Stern RG, Apter S, Davis KL . (1993): Effect of neuroleptic medication on cerebrospinal fluid monoamine metabolite concentrations in schizophrenia. Arch Gen Psychiatry 50: 599–605
Kahn RS, Davidson M, Siever LJ, Sevy S, Davis KL . (1994a): Clozapine treatment and its effect on neuroendocrine responses induced by the serotonin agonist, m-chlorophenylpiperazine. Biol Psychiatry 35: 909–912
Kahn RS, Harvey PD, Davidson M, Keefe RSE, Apter S, Neale JM, Mohs RC, Davis KL . (1994b): Neuropsychological correlates of central monoamine function in chronic schizophrenia: relationship between CSF metabolites and cognitive function. Schizophrenia Research 11: 217–224
Kapur S, Remington G . (1996): Serotonin-dopamine interaction and its relevance to schizophrenia. Am J Psychiatry 153: 466–476
Kay SR, Fiszbein A, Opler LA . (1987): The positive and Negative Syndrome Scale (PANSS) for schizophrenia. Schizophr Bull 13: 261–276
Kelland MD, Freeman AS, Chiodo LA . (1990): Serotonergic afferent regulation of the basic physiology and pharmacological responsiveness of nigrostriatal dopamine neurons. J Pharmacol Exp Ther 253: 803–811
Lieberman JA, Kane JM, Safferman AZ, Pollack S, Howard A, Szymanski S, Masiar SJ, Kronig MH, Cooper T, Novacenko H . (1994): Predictors of response to clozapine. J Clin Psychiatry 55[9, suppl B]:126–128
Lieberman JA, Koreen AR . (1993): Neurochemistry and neuroendocrinology of schizophrenia: a selective review. Schizophr Bull 19: 371–429
Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE . (1998): A decade of serotonin research: role of serotonin in treatment of psychosis. Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44: 1099–1117
Lindstrom LH . (1985): Low HVA and normal 5-HIAA CSF levels in drug-free schizophrenic patients compared to healthy volunteers: correlations to symptomatology and family history. Psychiatry Res 14: 265–273
Meltzer HY . (1989): Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99: S18–S27
Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H . (1997): Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58(suppl 10):37–44
Moore NA, Rees G, Sanger G, Tye NC . (1994): Effects of olanzapine and other antipsychotic agents on responding maintained by a conflict schedule. Behav Pharmacol 5: 196–202
Nordin C, Eklundh T, Fernstrom V, Swedin A, Zachau AC . (1995): Gradients of CSF monoamine metabolites: a comparison between male and female volunteers. J Psych Res 29: 133–140
Pickar D, Owen RR, Litman RE, Konicki E, Gutierrez R, Rapaport MH . (1992): Clinical and biologic response to clozapine in patients with schizophrenia. Arch Gen Psychiatry 49: 345–353
Potter WZ, Manji HK . (1993): Are monoamine metabolites in cerebrospinal fluid worth measuring? Arch Gen Psychiatry 50: 653–656
Priestley JV, Somogyi P, Cuello AC . (1981): Neurotransmitter-specific projection neurons revealed by combining PAP immunohistochemistry with retrograde transport of HRP. Brain Res 220: 231–240
Risby ED, Hsiao JW, Sunderland T, Agren H, Rudorfer MV, Potter WZ . (1987): The effects of antidepressants on the cerebrospinal fluid homovanillic acid/5-hydroxyindoleacetic acid ratio. Clin Pharmacol Ther 42: 547–554
Risch SC, Lewine RRJ . (1993): Low cerebrospinal fluid homovanillic acid-5-hydroxyindoleacetic acid ratio predicts clozapine efficacy: a replication. Arch Gen Psychiatry 50: 670
Risch SC, Lewine RRJ . (1995): Clozapine therapy and increases in homovanillic acid. Arch Gen Psychiatry 52: 244
Roth BL, Meltzer HY . (1995): The role of serotonin in schizophrenia. In Bloom FE, Kupfer DJ (eds), Psychopharmacology: the fourth generation of progress. New York, Raven Press, pp 1215–1227
Schmidt CJ, Sorensen SM, Kehne JH, Carr AA, Palfreyman MG . (1995): The role of 5-HT2a receptors in antipsychotic activity. Life Sci 56: 2209–2222
Sedvall G, Fyro B, Nyback H, Wiesel FA, Wode-Helgodt B . (1974): Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of schizophrenic patients during treatment with antipsychotic drugs. J Psychiat Res 11: 75–80
Sharma RP, Javaid JI, Janicak PG, Davis JM, Faull K . (1993): Homovanillic acid in the cerebrospinal fluid: patterns of response after four weeks of neuroleptic treatment. Biol Psychiatry 34: 128–134
Sharma R, Javaid JI, Janicak P, Faull K, Comaty J, Davis JM . (1989): Plasma and CSF HVA before and after pharmacological treatment. Psychiatry Res 28: 97–104
Silver R, LeSauter J, Tresco PA, Lehman MN . (1996): A diffusible coupling signal from transplanted suprachiasmatic nucleus controlling circadian locomotor rhythms. Nature 382: 810–813
Stanley M, Traskman-Bendz L, Dorovini-Zis K . (1985): Correlations between aminergic metabolites simultaneously obtained from human CSF and brain. Life Sci 37: 1279–1286
Szymanski S, Lieberman J, Pollack S, Munne R, Saferman A, Kane J, Kronig M, Cooper T . (1993): The dopamine-serotonin relationship in clozapine response. Psychopharmacology 112: S85–S89
Ternaux JP, Hery F, Bourgoin S, Adrien J, Glowinski J, Hamon M . (1977): The topographical distribution of serotonergic terminals in the neostriatum of the rat and the caudate nucleus of the cat. Brain Res 121: 311–326
Törk I . (1991): Anatomy of the serotonergic system. Ann NY Acad Sci 600: 9–34
van Kammen DP, van Kammen WB, Mann LS, Seppala T, Linnoila M . (1986): Dopamine metabolism in the cerebrospinal fluid of drug-free schizophrenic patients with and without cortical atrophy. Arch Gen Psychiatry 43: 978–983
Weinberger DR, Berman KF, Illowsky BP . (1988): Physiological dysfunction of dorsolateral prefrontal cortex in schizophrenia III: a new cohort and evidence for monoaminergic mechanism. Arch Gen Psychiatry 45: 609–615
Weir RL, Chase TN, Ng LKY, Kopin IJ . (1973): 5-Hydroxyindoleacetic acid in the spinal fluid, relative contribution from brain and spinal cord. Brain Res 52: 409–412
Westenberg HGM, Verhoeven WMA . (1988): CSF monoamine metabolites in patients and controls: support for a bimodal distribution in major affective disorders. Acta Psychiatr Scand 78: 541–549
Westerlink BHC, Kikkert RJ . (1986): Effects of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J Neurochem 46: 1145–1152
Wester P, Bergstrom U, Eriksson A, Gezellius C, Hardy J, Winblad B . (1990): Ventricular cerebrospinal fluid monoamine transmitter and metabolite concentrations reflect human brain neurochemistry in autopsy cases. J Neurochem 54: 1148–1156
Wiesel FA, Nordstrom AL, Farde L, Eriksson B . (1994): An open clinical and biochemical study of ritanserin in acute patients with schizophrenia. Psychopharmacology 114: 31–38
Wieselgren IM, Lindstrom LH . (1998): CSF levels of HVA and 5-HIAA in drug-free schizophrenic patients and healthy controls: a prospective study focused on their predictive value for outcome in schizophrenia. Psychiatry Res 81: 101–110
Wode-Helgodt B, Fyro B, Gullberg B, Sedvall G . (1977): Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid in psychotic patients. Acta Psychiatr Scand 56: 129–142
Wood JH . (1980): Neurochemical analysis of cerebrospinal fluid. Neurology 30: 645–651
Acknowledgements
This study was supported by Eli Lilly International, clinical research. We thank H. J. Wynne, Ph.D., for his statistical advice.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Scheepers, F., Gispen-de Wied, C., Westenberg, H. et al. The Effect of Olanzapine Treatment on Monoamine Metabolite Concentrations in the Cerebrospinal Fluid of Schizophrenic Patients. Neuropsychopharmacol 25, 468–475 (2001). https://doi.org/10.1016/S0893-133X(01)00250-0
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1016/S0893-133X(01)00250-0
Keywords
This article is cited by
-
Cerebrospinal fluid levels of 5-HIAA and dopamine in people with HIV and depression
Journal of NeuroVirology (2023)
-
Cerebrospinal fluid monoamine metabolite profiles in bipolar disorder, ADHD, and controls
Journal of Neural Transmission (2017)
-
d-amino acid oxidase activator gene (DAOA) variation affects cerebrospinal fluid homovanillic acid concentrations in healthy Caucasians
European Archives of Psychiatry and Clinical Neuroscience (2012)
-
Cerebrospinal fluid biomarker candidates of schizophrenia: where do we stand?
European Archives of Psychiatry and Clinical Neuroscience (2012)
-
Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia
Molecular Psychiatry (2010)
